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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient-reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report results 
of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Czech language. The 
reading comprehension of the questionnaire was tested in ten JIA parents and patients. The participating centre was asked 
to collect demographic and clinical data along the JAMAR questionnaire in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical 
validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the three Likert assumptions, 
floor/ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct 
validity (convergent and discriminant validity). A total of 103 JIA patients (5.8% systemic, 35.9% oligoarticular, 37.9% 
RF-negative polyarthritis, 20.4% other categories) and 100 healthy children, were enrolled. The JAMAR components dis-
criminated well healthy subjects from JIA patients. Notably, there was no significant difference between healthy subjects and 
their affected peers in the school-related problems variable and in the Psychosocial Health of the Paediatric Rheumatology 
Quality of Life scale. All JAMAR components revealed good psychometric performances. In conclusion, the Czech version 
of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for use both in routine clinical practice 
and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Czech parent, child/adult version of the 
Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthri-
tis (JIA). The JAMAR assesses the most relevant parent/
patient-reported outcomes in JIA, including overall well-
being, functional status, health-related quality of life 
(HRQoL), pain, morning stiffness, disease activity/status/
course, articular and extra-articular involvement, drug-
related side effects/compliance and satisfaction with ill-
ness outcome.
This project was part of a larger multinational study 
conducted by the Paediatric Rheumatology International 
Trials Organisation (PRINTO) [2] aimed to evaluate the 
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epidemiology, outcome and treatment of childhood arthritis 
(EPOCA) in different geographic areas [3].
We report herein results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Czech language.
Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from September 
2011 to December 2012. Children were recruited after Eth-
ics Committee approval and consent from at least one parent.
The JAMAR
The JAMAR (1) includes the following 15 sections:
 1. Assessment of physical function (PF) using 15 items 
in which the ability of the child to perform each task is 
scored as follows: 0 = without difficulty, 1 = with some 
difficulty, 2 = with much difficulty, 3 = unable to do and 
not applicable if it was not possible to answer the ques-
tion or the patient was unable to perform the task due 
to their young age or to reasons other than JIA. The 
total PF score ranges from 0 to 45 and has 3 com-
ponents: PF-lower limbs (PF-LL); PF-hand and wrist 
(PF-HW) and PF-upper segment (PF-US) each scor-
ing from 0 to 15 [7]. Higher scores indicating higher 
degree of disability [8–10].
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle Visual Analogue Scale (VAS) 
[11].
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint).
 4. Assessment of morning stiffness (present/absent).
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent).
 6. Rating of the level of disease activity on a 21-circle 
VAS.
 7. Rating of disease status at the time of the visit (cat-
egorical scale).
 8. Rating of disease course from previous visit (categori-
cal scale).
 9. Checklist of the medications the patient is taking (list 
of choices).
 10. Checklist of side effects of medications.
 11. Report of difficulties with medication administration 
(list of items).
 12. Report of school/university/work problems caused by 
the disease (list of items).
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (five 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score = 0), ‘sometimes’ (score = 1), ‘most of the time’ 
(score = 2) and ‘all the time’ (score = 3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0–15) can be calculated [12–14].
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS.
 15. A question about satisfaction with the outcome of the 
illness (yes/no) [15].
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of ten JIA parents 
and ten patients.
The participating centre was asked to collect demo-
graphic and clinical data along the JAMAR questionnaire 
in 100 consecutive JIA patients or all consecutive patients 
seen in a 6-month period and to administer the JAMAR 
to 100 healthy children and their parents. The statistical 
validation phase explored the descriptive statistics and the 
psychometric issues [16]. In particular, we evaluated the 
following validity components: the first Likert assump-
tion [mean and standard deviation (SD) equivalence]; the 
second Likert assumption or equal item–scale correla-
tions (Pearson r: all items within a scale should contribute 
equally to the total score); third Likert assumption (item 
internal consistency or linearity for which each item of 
a scale should be linearly related to the total score that 
is 90% of the items should have Pearson r ≥ 0.4); floor/
ceiling effects (frequency of items at lower and higher 
extremes of the scales, respectively); internal consistency, 
measured by the Cronbach’s alpha, interscale correlation 
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(the correlation between two scales should be lower than 
their reliability coefficients, as measured by Cronbach’s 
alpha); test–retest reliability or intra-class correlation coef-
ficient (reproducibility of the JAMAR repeated after 1 or 
2 weeks); and construct validity in its two components: 
the convergent or external validity which examines the 
correlation of the JAMAR subscales with the six JIA core 
set variables, with the addition of the parent assessment 
of disease activity and pain by the Spearman’s correlation 
coefficients (r) [17] and the discriminant validity, which 
assesses whether the JAMAR discriminates between the 
different JIA categories and healthy children [18].
Quantitative data were reported as medians with 1st and 
3rd quartiles and categorical data as absolute frequencies 
and percentages.
The complete Czech parent and patient versions of the 
JAMAR are available upon request to PRINTO.
Results
Cross‑cultural adaptation
The Czech JAMAR was fully cross-culturally adapted 
from the standard English version with two forward and 
two backward translations with a concordance for 113/123 
translations lines (91.9%) for the parent version and 
119/120 lines (99%) for the child version.
In the probe technique analysis, all 123 lines were 
understood by at least 80% of the parents (median 100%; 
range 90–100%). All the 120 lines of the patient version 
of the JAMAR were understood by at least 80% of the 
children (median 100%; range 100–100%). The texts of the 
parent JAMAR and of the child JAMAR were unmodified 
after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 103 JIA patients and 100 healthy children (total 
of 203 subjects), were enrolled at the paediatric rheumatol-
ogy centre.
In the 103 JIA subjects, the JIA categories were 5.8% 
with systemic arthritis, 35.9% with oligoarthritis, 37.9% 
with RF-negative polyarthritis, 1.0% with RF-positive pol-
yarthritis, 2.9% with psoriatic arthritis, 12.6% with enthesi-
tis-related arthritis and 3.9% with undifferentiated arthritis 
(Table 1).
A total of 202/203 (99.5%) subjects had the parent ver-
sion of the JAMAR completed by a parent (103 from parents 
of JIA patients and 99 from parents of healthy children). The 
JAMAR was completed by 178/202 (88.1%) mothers and 
24/202 (11.9%) fathers. The child version of the JAMAR 
was completed by 163/203 (80.3%) children aged five or 
older. Also patients younger than 7 years, capable to assess 
their personal condition and able to read and write, were 
asked to fill in the patient version of the questionnaire.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The fol-
lowing results section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that 
did not allow skipping answers and input of null values. 
The response pattern for both PF and HRQoL was posi-
tively skewed toward normal functional ability and normal 
HRQoL. All response choices were used for the different 
HRQoL items except for items 1, 6, 7 and 8, whereas a 
reduced number of response choices was used for all the PF 
items except for items 1, 3, 4 and 10.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items, 
except for HRQoL item 8 (data not shown). The median 
number of items marked as not applicable was 0% (0–0%) 
for the PF and 1% (1–3%) for the HRQoL.
Floor and ceiling effect
The median floor effect was 94.2% (88.3–96.1%) for the 
PF items, 70.9% (52.4–74.8%) for the HRQoL-PhH items, 
and 71.8% (67.0–75.7%) for the HRQoL-PsH items. The 
median ceiling effect was 0% (0–1%) for the PF items, 3.9% 
(1.9–3.9%) for the HRQoL-PhH items, and 0% (0–1%) for 
the HRQoL-PsH items. The median floor effect was 53.4% 
for the pain VAS, 47.6% for the disease activity VAS and 
44.7% for the well-being VAS. The median ceiling effect 
was 0% for the pain VAS, 0% for the disease activity VAS 
and 0% for the well-being VAS.
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Table 1  Descriptive statistics (medians, 1st–3rd quartiles or absolute frequencies and %) for the 103 JIA patients
Data related to the JAMAR refers to the 103 JIA patients and to the 99 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS Visual Analogue 
Scale (score 0–10; 0 = no activity; 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health-related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refer to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic 
(N = 6)
Oligoarthritis 
(N = 37)
RF− pol-
yarthritis 
(N = 39)
RF+ polyar-
thritis (N = 1)
Psoriatic 
arthritis 
(N = 3)
Enthesitis 
related-arthri-
tis (N = 13)
Undifferenti-
ated arthritis 
(N = 4)
All JIA 
patients 
(N = 103)
Healthy 
(N = 100)
Female 1 (16.7%) 24 (64.9%) 29 (74.4%) 1 (100%) 1 (33.3%) 2 (15.4%) 3 (75%) 61 (59.2%) 58 (58%)
Age at visit 13.3 (11.5–
14.3)
10.3 
(7.3–14.4)
9.6 (6.1–14.9) 18.9 (18.9–
18.9)
12.9 (5–13.1) 13.5 (12.3–
15.7)
12.5 (11.6–
13.6)
11.6 
(7.5–14.5)
10.4 (9.1–
13.3)
Age at onset 9.8 (8–10) 3.1 (2–8.2) 4.6 (2.5–7.6) 15.7 (15.7–
15.7)
6.4 (3–12.5) 9 (8.4–10.4) 8.4 (7.4–9.3) 5.8 (2.8–
8.8)**
Disease duration 3.1 (1.6–4.5) 4.9 (1.9–7.5) 4.9 (2.3–6.8) 3.1 (3.1–3.1) 2 (0.4–6.7) 4.3 (3.1–4.9) 4 (3.2–5.3) 4.5 (2–6.8)
ESR 10 (5–24) 5 (4–10) 10 (5–23) – 10 (6–14) 8 (7–10) 20.5 (18–23) 9 (5–15)
MD VAS 
(0–10 cm)
0 (0–1) 0 (0–0.5) 0 (0–2) 4 (4–4) 1.5 (0–3) 0.5 (0–3) 0.3 (0–0.8) 0 (0–1.5)
No. swollen joints 0 (0–0) 0 (0–0) 0 (0–1) 2 (2–2) 2 (0–2) 1 (0–2) 0 (0–0) 0 (0–1)*
No. joints with 
pain
0 (0–0) 0 (0–0) 0 (0–0) 2 (2–2) 0 (0–1) 0 (0–3) 0 (0–0.5) 0 (0–0)
No. joints with 
LOM
0 (0–0) 0 (0–1) 0 (0–2) 4 (4–4) 0 (0–4) 1 (0–4) 1 (0–3) 0 (0–2)
No. active joints 0 (0–0) 0 (0–1) 0 (0–2) 2 (2–2) 2 (0–2) 1 (0–4) 0 (0–0.5) 0 (0–1)*
Active systemic 
features
1 (16.7%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 1 (7.7%) 0 (0%) 2 (1.9%)
ANA status 0 (0%) 7 (18.9%) 11 (28.2%) 1 (100%) 1 (33.3%) 1 (7.7%) 0 (0%) 21 (20.4%)
Uveitis 0 (0%) 3/36 (8.3%) 7 (17.9%) 0 (0%) 0 (0%) 3 (23.1%) 0 (0%) 13/101 
(12.9%)
PF total score 0.5 (0–2) 0 (0–2) 0 (0–1) 2 (2–2) 0 (0–7) 0 (0–3) 0 (0–0) 0 (0–2) 0 (0–0)#
Pain VAS 0 (0–0) 0.5 (0–1.5) 0 (0–1) 1.5 (1.5–1.5) 0 (0–5) 1 (0–3) 0.3 (0–1.8) 0 (0–1.5) 0 (0–0)#
Disease activity 
VAS
0 (0–0) 1 (0–1.5) 0 (0–1.5) 2.5 (2.5–2.5) 0 (0–3) 1 (0–2) 0.3 (0–1.8) 0.5 (0–1.5)
Well-being VAS 0 (0–2) 1 (0–2) 0 (0–1.5) 0 (0–0) 2.5 (0.5–3) 0 (0–2) 0.5 (0.3–1.8) 0.5 (0–2)
HRQoL-PhH 1 (0–1) 2 (0–3) 1 (0–3) 1 (1–1) 3 (3–14) 1 (0–5) 0.5 (0–1.5) 1 (0–3) 0 (0–1)#
HRQoL-PsH 1.5 (0–3) 1 (0–3) 0 (0–2) 0 (0–0) 8 (1–8) 0 (0–1) 1.5 (0–3.5) 1 (0–3) 0 (0–1)
HRQoL total 
score
2.5 (0–4) 3 (1–6) 2 (0–5) 1 (1–1) 11 (4–22) 2 (0–10) 3 (1–4) 3 (0–5) 0 (0–2)#
Pain/swell. in > 1 
joint
1 (16.7%) 17 (45.9%) 16 (41%) 1 (100%) 1 (33.3%) 9 (69.2%) 1 (25%) 46 (44.7%) 6 (6.1%)#
Morning stiff-
ness > 15 min
1 (16.7%) 3 (8.1%) 3 (7.7%) 0 (0%) 1 (33.3%) 3 (23.1%) 0 (0%) 11 (10.7%) 0 (0%)**
Subjective remis-
sion
1 (16.7%) 21 (56.8%) 16 (41%) 1 (100%) 1 (33.3%) 6 (46.2%) 1 (25%) 47 (45.6%)
In treatment 4 (66.7%) 27 (73%) 33 (84.6%) 1 (100%) 3 (100%) 8 (61.5%) 2 (50%) 78 (75.7%)
Reporting side 
effects
3/4 (75%) 8/27 (29.6%) 17/33 (51.5%) 1 (100%) 2 (66.7%) 2/8 (25%) 0 (0%)
Taking medication 
regularly
4/4 (100%) 24/27 (88.9%) 32/33 (97%) 1 (100%) 3 (100%) 8/8 (100%) 2/2 (100%)
With problems 
attending school
0 (0%) 0 (0%) 2/24 (8.3%) 0 (0%) – 0 (0%) 0 (0%) 2/60 (3.3%) 1 (1%)
Satisfied with dis-
ease outcome
5 (83.3%) 30 (81.1%) 31 (79.5%) 1 (100%) 2 (66.7%) 10 (76.9%) 4 (100%) 83 (80.6%)
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Equal item–scale correlations (second Likert 
assumption)
Pearson’s item–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 87% of the PF 
items, with the exception of PF items 14 and 15, for 100% of 
the HRQoL items and for 100% of the HRQoL items.
Items internal consistency (third Likert assumption)
Pearson’s item–scale correlations were ≥ 0.4 for 87% of items 
of the PF (except for PF items 14 and 15) and for 100% of 
items of the HRQoL.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS Visual analogue Scale, PF physical func-
tion, HRQoL health-related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent (N = 103/203) Child (N = 87/163)
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 94.2% 95.4%
 HRQoL-PhH 70.9% 77.0%
 HRQoL-PsH 71.8% 77.0%
 Pain VAS 53.4% 46.0%
 Disease activity VAS 47.6% 48.3%
 Well-being VAS 44.7% 46.0%
Ceiling effect, median
 PF 0.0% 0.0%
 HRQoL-PhH 3.9% 3.4%
 HRQoL-PsH 0.0% 0.0%
 Pain VAS 0.0% 0.0%
 Disease activity VAS 0.0% 0.0%
 Well-being VAS 0.0% 0.0%
Items with equivalent item–scale correlation 87% for PF, 100% for HRQoL 87% for PF, 100% for HRQoL
Items with item–scale correlation ≥ 0.4 87% for PF, 100% for HRQoL 93% for PF, 100% for HRQoL
Cronbach’s alpha
 PF-LL 0.87 0.84
 PF-HW 0.93 0.92
 PF-US 0.77 0.72
 HRQoL-PhH 0.91 0.88
 HRQoL-PsH 0.81 0.77
Items with item–scale correlation lower than the Cronbach’s alpha 100% for PF, 100% for HRQoL 93% for PF, 100% for HRQoL
Test–retest intraclass correlation
 PF total score 0.98 1.0
 HRQoL-PhH 0.89 1.0
 HRQoL-PsH 0.86 1.0
Spearman’s correlation with JIA core set variables, median
 PF 0.5 0.5
 HRQoL-PhH 0.4 0.3
 HRQoL-PsH 0.04 0.1
 Pain VAS 0.4 0.3
 Disease activity VAS 0.2 0.3
 Well-being VAS 0.4 0.3
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Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.87 for PF-LL, 0.93 for PF-HW, 0.77 
for PF-US. Cronbach’s alpha was 0.91 for HRQoL-PhH and 
0.81 for HRQoL-PsH.
Interscale correlation
The Pearson’s correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales of the 
questionnaires was lower than the Cronbach’s alpha.
Test–retest reliability
Reliability was assessed in 20 JIA patients, by re-administer-
ing both versions (parent and child) of the JAMAR after a 
median of 2 days (2–2 days). The intraclass correlation coef-
ficients (ICC) for the PF total score showed an almost perfect 
reproducibility (ICC 0.98). The ICC for the HRQoL-PhH and 
HRQoL-PsH scores showed an almost perfect reproducibility 
(ICC 0.89 and 0.86, respectively).
Convergent validity
The Spearman’s correlation of the PF total score with the JIA 
core set of outcome variables ranged from 0.4 to 0.7 (median 
0.5). The PF total score best correlation was observed with the 
parent assessment of pain (r = 0.7, p < 0.001). For the HRQoL, 
the median correlation of the PhH with the JIA core set of out-
come variables ranged from 0.2 to 0.7 (median 0.4), whereas 
for the PsH ranged from − 0.1 to 0.2 (median 0.04). The PhH 
showed the best correlation with the parent’s assessment of 
pain (r = 0.7, p < 0.001) and the PsH with the parent global 
assessment of well-being (r = 0.45, p < 0.001). The median 
correlations between the pain VAS, the well-being VAS, 
and the disease activity VAS and the physician-centered and 
laboratory measures were 0.4 (0.2–0.5), 0.2 (0.04–0.3), 0.4 
(0.2–0.5), respectively.
Discussion
In this study, the Czech version of the JAMAR was cross-
culturally adapted from the original standard English 
version with two forward and two backward translations. 
According to the results of the validation analysis, the 
Czech parent and patient versions of the JAMAR possess 
satisfactory psychometric properties. The disease-spe-
cific components of the questionnaire discriminated well 
between patients with JIA and healthy controls. Notably 
there is no significant difference between the healthy sub-
jects and their affected peers in the psychosocial quality 
of life and school-related problems variables. This finding 
indicates that children with JIA adapt well to the conse-
quences of JIA.
Psychometric evaluation was good for all domains with 
few exceptions: two PF items (“bend head back” and “bite a 
sandwich or an apple”) showing a lower items internal con-
sistency. However the overall internal consistency was good 
for all the domains. In the external validity evaluation, the 
Spearman’s correlations of the PF and HRQoL scores with 
JIA core set parameters ranged from very weak to moderate.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Czech version of the JAMAR was 
found to have satisfactory psychometric properties and it 
is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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